# A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults

> **NCT02676895** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 74 (actual)

## Conditions studied

- Shigella Sonnei Infection

## Interventions

- **BIOLOGICAL:** GVGH S. sonnei (1790GAHB) vaccine 25 μg
- **BIOLOGICAL:** GVGH S. sonnei (1790GAHB) vaccine 100 μg
- **BIOLOGICAL:** Menveo
- **BIOLOGICAL:** Boostrix

## Key facts

- **NCT ID:** NCT02676895
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-08
- **Primary completion:** 2017-03-10
- **Final completion:** 2017-03-10
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2019-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02676895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02676895, "A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02676895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*